The impact of transition on public health is difficult to correlate precisely with socioeconomic and political change. The inability to manage the spread of HIV is one example of the way Ukraine's health system has been adversely affected by transition. HIV/AIDS is relatively new to the country, appearing in the mid-1990s, rising dramatically between 1995 and 2002, and continuing to rise at exponential rates ( fig 1) . The transmission route for infection was originally injecting drug use, mainly in young men, but infection is now spreading via unprotected heterosexual sex. 5 We investigate the link between HIV infection, now at epidemic levels, and human and economic development in Ukraine as a case study of the impact of transition on health.
Health infrastructure
Ukraine has no public health information service, no sexual health education in its schools, and no national information dissemination strategy for HIV/AIDS. At least a decade of corruption within the former Kuchma government has had a deleterious effect on development of public services, including the health system. 6 Investment is mainly absorbed in maintaining large hospitals, a continuation of the pre-transition approach to health care. Communicable diseases carry a stigma within the population, and no public health policy exists to fund HIV information, prevention, care, or treatment.
UNAIDS/WHO estimates that for the Eastern European and Central Asia region to avert continuous spread of infection and to treat those people who are already infected, funding should be scaled up from about $300m to $1.5bn (from £166m to £900m; €250m to €750m) by 2007, to reflect 2-3% of a national health budget. Of the region's funding, 60% is needed for Ukraine, Russia, and Kazakhstan. 7 Investment in healthcare services in Ukraine is generally inadequate, even when compared within the Eastern European and Central Asia region. The most recent available figures (for 2001) show 2.9% of Ukraine's gross domestic product spent on public health care and 1.4% on private health care; the corresponding figures for the Russian Federation were 3.7% and 1.7%. 
Attitudes to prevention and treatment of AIDS
Public awareness of HIV risk is low, a consequence of the government's neglect of public health. Lack of investment, widespread poverty, social and judicial constraints on decriminalisation of drug use, drug trafficking, and government corruption have been key influencing factors.
Cultural attitudes toward injecting drug users, sex workers, same sex relationships, immigrants, and people with communicable diseases remain punitive. At the same time, the country has experienced steep rises in injecting drug use, the initial transmission route for HIV. Corrupt border controls and drug trafficking have been internationally recognised features in Ukraine until recently. There is hope among the population that the new government under President Viktor Yushchenko, elected in December 2004, will change this profile. The health system in Ukraine Injecting drug use remains criminalised, and the only treatment for addiction is via state mental health services or private psychosocial counselling services. No harm reduction programme is in place to help prevent HIV transmission.
Drug trafficking from the east, via the Black Sea, has produced an explosion in the numbers of intravenous drug users, and with it a spread in HIV, mainly in men, but infection is now rapidly moving into the heterosexual population. Our analysis of available data indicates that the River Dnieper is a permeable border: the five highest rates of intravenous drug users, in Dnipropetrovsk, Odesa, Kiev, Mikolaiv, and Zaporizhzhia, all lie along the Dnieper (fig 2, table 1) . 9 Targeting health care and treatment, information, and harm reduction programmes along this corridor would be a valuable first step.
The numbers of officially registered intravenous drug users inevitably under-report actual intravenous drug users (table 1) . Because injecting drug users do not receive care or treatment, incentives to register are minimal, and actual numbers are higher than officially registered numbers.
Poverty and wealth in Ukraine
The gap between rich and poor is extreme, even for a transition economy-the World Bank estimates that average earnings are $4650. The work force is well educated, yet labour costs are below $160 a month per worker (labour costs in neighbouring Poland are $400 a month). Low income is widespread despite national economic growth of at least 7.3% a year since 2000. At the same time, a small minority of the population has capitalised on the transition to a private enterprise economy. Dollar multimillionaires control business and industry, the economy, the media, and parliament. This new system of oligarchy within Ukraine, combined with citizens' frustration at levels of corruption, was the primary focus for the strongly contested elections in 2004.
The government's total tax revenue is low because the population relies heavily on a cash economy. In 2004, Kuchma's government reduced the higher rate tax from 40% to an overall 13%, thus favouring the wealthy. The government is not poor, but its revenue distribution has included no new investment for developing health care.
A combination of good macroeconomic policy from 2000 alongside a pattern of industrial ownership by a small number of private owners has produced a powerful group of wealthy Ukrainians. The consequence for health has been to create a wide gap between the seriously rich and the extremely poor. This favours private medicine at the expense of tax based or insurance based systems.
Poverty, the marginalisation of risk groups, and ignorance of the health implications of personal behaviour are the fuel that is ensuring spread of HIV. Furthermore, deaths from tuberculosis (which are also on the increase), hepatitis B and C, and causes of death associated with HIV are not necessarily registered as HIV/AIDS related where that is or may be the primary cause. difficult to ascertain which sectors of the population to target in order to reduce HIV transmission rates. The transmission of HIV and related infectious diseases threatens to deplete a generation of Ukrainian youth. In a country experiencing economic growth and considerable development potential, HIV/AIDS threatens to undermine the workforce, jeopardising a national resource on which the economy depends.
Population targeting
Largely because of the inadequacies of data collection, estimates of HIV infection and AIDS deaths vary considerably. Five years ago it was estimated that between 60 000 and 180 000 people were infected. 10 The high estimate of deaths thus far from AIDS is 33 000. 2 The rate of new infections is still rising, whereas in Russia, Estonia, and Moldova rates have declined since 2001. 2 Most data for surveillance of HIV/AIDS that include data from Ukraine are published outside the country. Evidence based on research within Ukraine is patchy and its quality varies between regions (oblasts). Despite sophisticated in-country expertise, the Ministry for Health has not used its in-country epidemiologists coherently.
Cultural attitudes to infection, alongside the absence of population care and treatment programmes, are likely to be leading to under-reporting. At present, parents tend to abandon infected babies to institutionalised state care. Reliable data are lacking for the numbers of children orphaned by HIV infected parents, but these numbers are likely to rise. Ukraine has no social care system to support vulnerable families, instead relying on large institutional "orphanages." 81  55  48  40  34  45  51  44  1499 5422 8934 8590 5830 6216 7009 8761 10 013 62 672   Ukrainian citizens  6  20  16  19  21  30  40  31  1490 5400 8913 8575 5827 6212 7000 8756 10 009 62 365   Foreign citizens  75  35  32  21  13  15  11  13  9  22  21  15  3  4  9  5 
Summary points
Ukraine has the highest per capita rate of HIV/AIDS infection in Europe, and this threatens the country's social and economic development
In Ukraine, HIV carries a severe social stigma, and public awareness of risk is low
Young people are at highest risk of new infection The economic collapse that followed "transition" has left high levels of poverty and inequality and poor investment in the development of the country's health system
Ukraine needs a national strategy for HIV/AIDS information, prevention, care, and treatment and needs improved in-country surveillance data for population targeting
Commentary: HIV is not just a transitional problem
Thomas E Novotny
The HIV and AIDS epidemic in eastern Europe and central Asia is changing. [1] [2] Despite data limitations, this region shows the fastest growth in HIV in the world. 3 At the end of 2004, between 920 000 and 2.1 million people in the region were living with HIV, compared with about 160 000 in 1995. Most countries in the region have low level epidemics, with less than 1% prevalence among pregnant women and less than 5% prevalence among high risk groups. The countries most affected are Ukraine, Russia, and the Baltic states, but incidence is also increasing elsewhere. The driving force in most countries has been intravenous drug use, but other contributors include migration, commercial sex work, increasing rates of sexually transmitted infection, widening economic disparities, and multiple high risk behaviours among prison populations.
Rhodes and Simic describe in detail the risk environment that prevails in eastern Europe and the western Balkans. 1 As national borders have been progressively opened, HIV risks have migrated across them along with people and goods, including illicit drugs. Civil society protections have not kept up with this globalisation, nor have legal frameworks that consider members of vulnerable groups as criminals or social deviants. But people with HIV infection are not deviants: they are predominantly young (more than 80% of new HIV cases occur in people younger than 30); they may be disenfranchised groups such as the Roma; they may be transport workers with sexually transmitted infection; and they are certainly heterosexual partners of intravenous drug users (the main bridge population).
DeBell and Carter (see p 216) describe how poverty and wealth disparities in Ukraine create fatalism and hopelessness about social risks and the exploding HIV epidemic. 2 There is a critical lack of investment in health systems and in effective national strategies to control the spread of HIV. Corruption, trafficking, and stigma triangulate to isolate HIV outside the mainstream of health systems, thus assuring that official action will be slow.
Global preventive opportunity
HIV in eastern Europe and central Asia is now on the agenda for the international health community. The Global Fund to Fight AIDS, Tuberculosis, and Malaria; the World Bank; and European and other bilateral donors have given grants. 4 It is rare that the international community has the opportunity to prevent an explosive problem, but that opportunity is at hand with HIV in eastern Europe. High level political commitment, attention to economic disparities, support for youth oriented programmes, programmes to reduce harm, and increased responsiveness of transitional health systems are all key components of HIV prevention. Without such bold actions, HIV will become an important and devastating long term problem for transitional health systems.
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